SBIR/STTR Research Award
Minimally Invasive Local Delivery of Cardiac Gene Therapy
Award amount
$1,293,419Program and phase
STTR · Phase IIAward year
2025Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Corami Biotech
- Proposal award date
- 2025-09-01
- Contract end date
- 2027-08-31
- UEI
- V4UYGDK9NEB3
- Solicitation number
- PA24-247
- Topic code
- NHLBI
Research abstract
PROJECT SUMMARY Cardiovascular diseases (CVD) are the leading cause of death in the United States, and current therapies are hindered by inefficient delivery methods, high systemic off-target exposure, and prohibitive costs, particularly for gene therapies. Corami Biotech’s platform combines a minimally invasive epicardial delivery device (EpiCor™) and a tunable hydrogel (GelCor™) which together localize therapeutic to the heart leading to significantly lower effective dose of gene therapy compared to systemic delivery while minimizing off-target expression.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications